术前68Ga-uPAR PET/CT对可切除非小细胞肺癌术后复发的预后价值
结果显示肿瘤68Ga-uPAR SUVmax和uPAR H-score与复发相关,而18F-FDG摄取无预后价值,提示uPAR PET可反映与侵袭相关的肿瘤生物学。
要点
- 68Ga-uPAR SUVmax每增加1单位,复发风险比为2.16(95%CI 1.34-3.49,P=0.002)。
- uPAR H-score每增加1单位,复发风险比为1.04(95%CI 1.01-1.08,P=0.017)。
- 18F-FDG摄取在本队列中未显示预后价值,需外部验证。
核心结论
- 术前68Ga-uPAR PET摄取反映肿瘤uPAR表达,并与术后早期复发相关。
- 18F-FDG摄取在该队列中不是预后因素。
- uPAR PET可捕捉葡萄糖代谢成像未完全反映的侵袭相关肿瘤生物学。
研究设计与样本
- 单中心前瞻性队列研究,纳入可切除肺腺癌或鳞状细胞癌患者。
- 患者在标准18F-FDG PET/CT基础上另行术前68Ga-uPAR PET/CT。
- 主要终点为术后复发,采用竞争风险框架分析,死亡为竞争事件。
- 主要预后分析以连续变量纳入单因素病因特异性Cox模型。
主要发现
- 68Ga-uPAR摄取与肿瘤组织uPAR表达相关,而18F-FDG摄取不相关。
- 68Ga-uPAR SUVmax较高与复发相关(HR 2.16,95%CI 1.34-3.49,P=0.002)。
- uPAR H-score较高与复发相关(HR 1.04/单位,95%CI 1.01-1.08,P=0.017)。
- 68Ga-uPAR SUVmean关联为边缘性(P=0.053),18F-FDG摄取无预后价值。
关键数值与推荐
- 探索性1.5年阈值分析显示高SUVmean组和高H-score组早期复发更多。
- SUVmax的1.5年阈值比较未达统计学显著性。
临床怎么用
- 对于可切除肺癌患者,术前68Ga-uPAR PET/CT可能有助于识别高早期复发风险者。
- 结果需外部验证后方可用于临床决策。
局限性
- 1.5年阈值分析为探索性,SUVmax比较未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-small cell lung cancer shows wide variability in outcomes after curative-intent resection. 18F-FDG PET/CT is indispensable for staging but primarily reflects glucose metabolism rather than the invasion-related tumor biology that may contribute to recurrence. 68Ga-NOTA-AE105 PET/CT images the urokinase-type plasminogen activator receptor (uPAR), a cell-surface mediator of local invasion and metastatic spread. We assessed whether preoperative 68Ga-uPAR PET/CT is prognostic for postoperative recurrence. Methods: We conducted a single-center cohort study of patients with resectable lung adenocarcinoma or squamous cell carcinoma who were prospectively enrolled to undergo preoperative 68Ga-uPAR PET/CT in addition to standard-of-care 18F-FDG PET/CT. Primary tumor SUVmean and SUVmax were measured for both tracers, and tumor tissue uPAR expression was quantified by immunohistochemistry (H-score). Postoperative recurrence was the primary endpoint and was analyzed in a competing-risks framework with death as a competing event. The primary prognostic analyses evaluated 68Ga-uPAR SUVs, 18F-FDG SUVs, and uPAR H-score as continuous variables using univariable cause-specific Cox models. A 1.5-y horizon was used for exploratory Youden-derived high versus low groups, for which cumulative incidence of recurrence was estimated using the Aalen-Johansen method. Trial registration number is NCT02755675 Results: Thirty-seven patients comprised the analysis cohort, of whom 14 developed recurrence during a median follow-up of 2.38 y (interquartile range, 1.97-8.20 y). Four patients died without prior recurrence. 68Ga-uPAR uptake correlated with tumor tissue uPAR expression, whereas 18F-FDG uptake did not. As continuous prognostic factors, higher 68Ga-uPAR SUVmax (hazard ratio, 2.16; 95% CI, 1.34-3.49; P = 0.002) and higher uPAR H-score (hazard ratio, 1.04 per unit; 95% CI, 1.01-1.08; P = 0.017) were associated with recurrence; 68Ga-uPAR SUVmean showed borderline evidence of association (P = 0.053), whereas 18F-FDG uptake was not prognostic. Exploratory 1.5-y threshold analyses showed greater early recurrence in the high SUVmean and high H-score groups; the SUVmax comparison did not reach statistical significance. Conclusion: Preoperative 68Ga-uPAR PET uptake reflected tumor uPAR expression and was associated with early postoperative recurrence, whereas 18F-FDG uptake was not prognostic in this cohort. These findings suggest that uPAR PET captures invasion-related tumor biology that is not fully reflected by glucose metabolism imaging. External validation is required.
引用
- Soldath P, Clausen MM, Loft A, et al. Prognostic Value of 68Ga-NOTA-AE105 uPAR PET/CT in Resected Non-Small Cell Lung Cancer: A Single-Center Prospective Study. J Nucl Med. 2026. PMID: 42914185. doi:10.2967/jnumed.126.272541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。